| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance JA McCubrey, LS Steelman, WH Chappell, SL Abrams, EWT Wong, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1773 (8), 1263-1284, 2007 | 3001 | 2007 |
| Evolution of cancer pharmacological treatments at the turn of the third millennium L Falzone, S Salomone, M Libra Frontiers in pharmacology 9, 1300, 2018 | 927 | 2018 |
| Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance JA McCubrey, LS Steelman, SL Abrams, JT Lee, F Chang, FE Bertrand, ... Advances in enzyme regulation 46 (1), 249-279, 2006 | 863 | 2006 |
| Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging LS Steelman, WH Chappell, SL Abrams, CR Kempf, J Long, P Laidler, ... Aging (Albany NY) 3 (3), 192, 2011 | 827 | 2011 |
| Cutaneous melanoma: From pathogenesis to therapy GC Leonardi, L Falzone, R Salemi, A Zanghì, DA Spandidos, ... International journal of oncology 52 (4), 1071-1080, 2018 | 732 | 2018 |
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health WH Chappell, LS Steelman, JM Long, RC Kempf, SL Abrams, RA Franklin, ... Oncotarget 2 (3), 135, 2011 | 692 | 2011 |
| GSK-3 as potential target for therapeutic intervention in cancer JA McCubrey, LS Steelman, FE Bertrand, NM Davis, M Sokolosky, ... Oncotarget 5 (10), 2881, 2014 | 555 | 2014 |
| Gut microbiota and cancer: from pathogenesis to therapy S Vivarelli, R Salemi, S Candido, L Falzone, M Santagati, S Stefani, ... Cancers 11 (1), 38, 2019 | 520 | 2019 |
| Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use GM Nitulescu, D Margina, P Juzenas, Q Peng, OT Olaru, E Saloustros, ... International journal of oncology 48 (3), 869-885, 2015 | 417 | 2015 |
| Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response JA McCubrey, LS Steelman, WH Chappell, SL Abrams, G Montalto, ... Oncotarget 3 (9), 954, 2012 | 384 | 2012 |
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance JA McCubrey, LS Steelman, WH Chappell, SL Abrams, RA Franklin, ... Oncotarget 3 (10), 1068, 2012 | 371 | 2012 |
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy LS Steelman, RA Franklin, SL Abrams, W Chappell, CR Kempf, J Bäsecke, ... Leukemia 25 (7), 1080-1094, 2011 | 331 | 2011 |
| Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia LS Steelman, SL Abrams, J Whelan, FE Bertrand, DE Ludwig, J Bäsecke, ... Leukemia 22 (4), 686-707, 2008 | 329 | 2008 |
| Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention NM Davis, M Sokolosky, K Stadelman, SL Abrams, M Libra, S Candido, ... Oncotarget 5 (13), 4603, 2014 | 326 | 2014 |
| Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy JA McCubrey, LS Steelman, SL Abrams, FE Bertrand, DE Ludwig, ... Leukemia 22 (4), 708-722, 2008 | 300 | 2008 |
| Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention JA McCubrey, LS Steelman, FE Bertrand, NM Davis, SL Abrams, ... Leukemia 28 (1), 15-33, 2014 | 281 | 2014 |
| Cancer-associated stroke: pathophysiology, detection and management E Dardiotis, AM Aloizou, S Markoula, V Siokas, K Tsarouhas, ... International journal of oncology 54 (3), 779-796, 2019 | 275 | 2019 |
| PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches G Ligresti, L Militello, LS Steelman, A Cavallaro, F Basile, F Nicoletti, ... Cell cycle 8 (9), 1352-1358, 2009 | 253 | 2009 |
| Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway AM Martelli, C Evangelisti, W Chappell, SL Abrams, J Bäsecke, F Stivala, ... Leukemia 25 (7), 1064-1079, 2011 | 252 | 2011 |
| Targeting the leukemic stem cell: the Holy Grail of leukemia therapy N Misaghian, G Ligresti, LS Steelman, FE Bertrand, J Bäsecke, M Libra, ... Leukemia 23 (1), 25-42, 2009 | 249 | 2009 |
